Detalhe da pesquisa
1.
Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.
J Clin Oncol
; 40(4): 369-381, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34860572
2.
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
Nat Med
; 28(4): 713-723, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35288695
3.
The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy.
Transplant Cell Ther
; 27(3): 233-240, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33781518
4.
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma.
Blood Cancer J
; 10(8): 79, 2020 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32759935
5.
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality.
Blood Adv
; 4(13): 3024-3033, 2020 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32614964
6.
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies.
Blood Adv
; 4(19): 4669-4678, 2020 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33002134
7.
Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
Nat Med
; 29(11): 2954, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36253610